Blue Fin Capital Inc. lessened its holdings in Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 8.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,831 shares of the life sciences company’s stock after selling 162 shares during the period. Blue Fin Capital Inc.’s holdings in Illumina were worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently made changes to their positions in ILMN. Private Trust Co. NA acquired a new stake in shares of Illumina in the 2nd quarter valued at $25,000. Glassman Wealth Services lifted its position in Illumina by 72.9% during the 2nd quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock worth $27,000 after buying an additional 62 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its position in Illumina by 50.0% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock worth $35,000 after buying an additional 61 shares in the last quarter. WASHINGTON TRUST Co lifted its position in Illumina by 100.0% during the 2nd quarter. WASHINGTON TRUST Co now owns 200 shares of the life sciences company’s stock worth $37,000 after buying an additional 100 shares in the last quarter. Finally, WFA of San Diego LLC acquired a new position in Illumina during the 2nd quarter worth about $37,000. Institutional investors and hedge funds own 87.97% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on the stock. Bank of America reduced their price target on shares of Illumina from $220.00 to $210.00 in a research report on Tuesday, January 10th. Citigroup downgraded shares of Illumina from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $200.00 to $180.00 in a research report on Monday, December 12th. StockNews.com initiated coverage on shares of Illumina in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Canaccord Genuity Group cut their target price on shares of Illumina from $340.00 to $330.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. Finally, Credit Suisse Group cut their target price on shares of Illumina from $230.00 to $225.00 and set a “neutral” rating on the stock in a research report on Friday, November 4th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $252.84.
Insider Buying and Selling
Illumina Stock Performance
Shares of ILMN stock opened at $204.39 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.93 and a quick ratio of 0.72. The stock has a market cap of $32.15 billion, a PE ratio of -7.74 and a beta of 1.14. The stock has a 50-day moving average of $207.79 and a 200-day moving average of $207.68. Illumina, Inc. has a one year low of $173.45 and a one year high of $383.98.
Illumina (NASDAQ:ILMN – Get Rating) last posted its earnings results on Thursday, November 3rd. The life sciences company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.05. Illumina had a positive return on equity of 4.36% and a negative net margin of 88.40%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.10 billion. As a group, sell-side analysts expect that Illumina, Inc. will post 2.23 earnings per share for the current year.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.